Corcept officer exercises and sells 3,700 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Corcept Therapeutics Chief Development Officer William Guyer exercised stock options to acquire 3,700 shares of common stock at $21.65 per share on August 4, 2026 and sold 3,700 shares at a weighted average price of $113.1248 per share under a Rule 10b5-1 plan adopted on November 27, 2024.
The options exercised were fully exercisable, and 126,300 option shares remained directly held after the transaction. The reported common stock position includes unvested restricted stock awards that each vest 100% on the one-year anniversary of their respective grant dates, subject to specified conditions.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) F4 | 3,700 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 3,700 | $21.65 | $80K |
| Sale | Common Stock F2, F3, F1 | 3,700 | $113.1248 | $419K |
Footnotes (4)
- F1. Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 877 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
- F2. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.
- F3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $112.92 to $113.455 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F4. Fully exercisable.
Key Figures
Key Terms
Rule 10b5-1 plan regulatory
restricted stock awards financial
weighted average sale price financial
Stock Option (right to buy) financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Corcept Therapeutics (CORT) report for William Guyer?
What option position does William Guyer retain in Corcept Therapeutics (CORT)?
What are the terms of William Guyer’s restricted stock awards at Corcept (CORT)?
AI-generated analysis. How Rhea-AI works. Not financial advice.